HIMS Stock Eyes Big Monthly Win: Novo Nordisk Calls Hims & Hers One Of Its Most ‘Voluminous’ Telehealth Partners
Hims had 2.6 million subscribers in Q1, up 9% year over year, with Q2 expected to show how…
HIMS Stock Extends 3-Day Rally: Hims & Hers Targets GLP-1 Gold Rush In Canada After Novo Nordisk Patent Expiry
The launch follows Novo Nordisk’s failure to pay a C$250 patent maintenance fee in Canada. Hims launched generic…
HIMS Stock Crashes Overnight After Brutal Q1 — But An Investor Says Novo, Lilly Deals Could Make It ‘Netflix Of Healthcare’
The investor said that Hims now has enough scale and capital to aggressively consolidate smaller telehealth rivals such…
After A Rough Week, HIMS May Have Found Its Catalyst – JPMorgan Sees ‘Compelling Path
JPMorgan initiated coverage of Hims & Hers with an ‘Overweight’ rating and a price target of $35, according…
CEO Targets 100K Monthly Wegovy Push After Novo Nordisk Truce
The development follows Novo Nordisk’s decision to drop its patent-infringement lawsuit tied to compounded GLP-1 offerings previously marketed…
Hims & Hers Opens Up Pre-Launch Waitlist For Ozempic And Wegovy Following Partnership With Novo Nordisk
The company stated that people who sign up for the waitlist will gain priority access to the official…
HIMS Stock Just Exploded — But the Real Story Might Be the Novo Nordisk Deal
Hims & Hers’ offices are located in one of those glass buildings in San Francisco, where startup…
Short Seller Who Bet Against Hims & Hers Now Says Its CEO ‘Wiped The Floor’ With Novo Nordisk
Hunterbrook had shorted Hims in 2024, warning its GLP-1 strategy relied on a regulatory loophole during drug shortages…
Novo Nordisk-Hims Deal Turns Wall Street Bullish — BMO Sees Relief From Commercial Headwinds, BofA Upgrades HIMS Stock
BMO Capital maintained its ‘Market Perform’ rating for Novo Nordisk, with a price target of $45, implying an…
HIMS Stock Soars After Novo Nordisk Drops Patent Infringement Lawsuit, Opens Access To Ozempic, Wegovy
Hims & Hers also stated that it will no longer advertise compounded GLP-1 offerings on its platform or…
Hims & Hers Burns $546M In Short Bets After Novo Nordisk Deal Sends Stock Soaring To Best Day Ever
Short interest totalled about $1.39 billion, or roughly 42.83% of the float, according to S3 Partners. Citigroup upgraded…
Hims & Hers stock surges on potential Novo Nordisk deal
Shares of Hims & Hers Health surged in premarket trading on Monday following reports that Novo Nordisk may…